Literature DB >> 25990623

Metastasis initiating cells in primary prostate cancer tissues from transurethral resection of the prostate (TURP) predicts castration-resistant progression and survival of prostate cancer patients.

Qinlong Li1, Quanlin Li2, Jill Nuccio3, Chunyan Liu1, Peng Duan1, Ruoxiang Wang1, Lawrence W Jones3, Leland W K Chung1,4, Haiyen E Zhau1.   

Abstract

BACKGROUND: We previously reported that the activation of RANK and c-Met signaling components in both experimental mouse models and human prostate cancer (PC) specimens predicts bone metastatic potential and PC patient survival. This study addresses whether a population of metastasis-initiating cells (MICs) known to express a stronger RANKL, phosphorylated c-Met (p-c-Met), and neuropilin-1 (NRP1) signaling network than bystander or dormant cells (BDCs) can be detected in PC tissues from patients subjected to transurethral resection of the prostate (TURP) for urinary obstruction prior to the diagnosis of PC with or without prior hormonal manipulation, and whether the relative abundance of MICs over BDCs could predict castration-resistant progression and PC patient survival.
METHODS: We employed a multiplexed quantum-dot labeling (mQDL) protocol to detect and quantify MICs and BDCs at the single cell level in TURP tissues obtained from 44 PC patients with documented overall survival and castration resistance status.
RESULTS: PC tissues with a higher number of MICs and an activated RANK signaling network, including increased expression of RANKL, p-c-Met, and NRP1 compared to BDCs, were found to correlate with the development of castration resistance and overall survival.
CONCLUSIONS: The assessment of PC cells with MIC and BDC phenotypes in primary PC tissues from hormone-naïve patients can predict the progression to castration resistance and the overall survival of PC patients.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  RANK signaling; dormant cells; metastasis-initiating cells; multiplexed quantum dot labeling; prostate cancer patient survival

Mesh:

Substances:

Year:  2015        PMID: 25990623      PMCID: PMC4736544          DOI: 10.1002/pros.23011

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  29 in total

Review 1.  Tumour stem cells and drug resistance.

Authors:  Michael Dean; Tito Fojo; Susan Bates
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

2.  Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway.

Authors:  Wen-Chin Huang; Zhihui Xie; Hiroyuki Konaka; Jaro Sodek; Haiyen E Zhau; Leland W K Chung
Journal:  Cancer Res       Date:  2005-03-15       Impact factor: 12.701

3.  Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer.

Authors:  Daniel Schramek; Andreas Leibbrandt; Verena Sigl; Lukas Kenner; John A Pospisilik; Heather J Lee; Reiko Hanada; Purna A Joshi; Antonios Aliprantis; Laurie Glimcher; Manolis Pasparakis; Rama Khokha; Christopher J Ormandy; Martin Widschwendter; Georg Schett; Josef M Penninger
Journal:  Nature       Date:  2010-09-29       Impact factor: 49.962

4.  Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit.

Authors:  Vincent Duheron; Estelle Hess; Monique Duval; Marion Decossas; Beatriz Castaneda; Jennifer E Klöpper; Leonela Amoasii; Jean-Baptiste Barbaroux; Ifor R Williams; Hideo Yagita; Josef Penninger; Yongwon Choi; Frédéric Lézot; Richard Groves; Ralf Paus; Christopher G Mueller
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-14       Impact factor: 11.205

Review 5.  Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status.

Authors:  H Bonkhoff
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

6.  Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer.

Authors:  Brenda K Edwards; Anne-Michelle Noone; Angela B Mariotto; Edgar P Simard; Francis P Boscoe; S Jane Henley; Ahmedin Jemal; Hyunsoon Cho; Robert N Anderson; Betsy A Kohler; Christie R Eheman; Elizabeth M Ward
Journal:  Cancer       Date:  2013-12-16       Impact factor: 6.860

7.  The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.

Authors:  T L Burgess; Y Qian; S Kaufman; B D Ring; G Van; C Capparelli; M Kelley; H Hsu; W J Boyle; C R Dunstan; S Hu; D L Lacey
Journal:  J Cell Biol       Date:  1999-05-03       Impact factor: 10.539

Review 8.  The many faces of neuroendocrine differentiation in prostate cancer progression.

Authors:  Stéphane Terry; Himisha Beltran
Journal:  Front Oncol       Date:  2014-03-25       Impact factor: 6.244

9.  RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization.

Authors:  Gina Chia-Yi Chu; Haiyen E Zhau; Ruoxiang Wang; André Rogatko; Xu Feng; Majd Zayzafoon; Youhua Liu; Mary C Farach-Carson; Sungyong You; Jayoung Kim; Michael R Freeman; Leland W K Chung
Journal:  Endocr Relat Cancer       Date:  2014-03-04       Impact factor: 5.678

Review 10.  β2-Microglobulin-mediated signaling as a target for cancer therapy.

Authors:  Takeo Nomura; Wen-Chin Huang; Haiyen E Zhau; Sajni Josson; Hiromitsu Mimata; Leland W K Chung
Journal:  Anticancer Agents Med Chem       Date:  2014-03       Impact factor: 2.505

View more
  5 in total

1.  Neuropilin 1 Receptor Is Up-Regulated in Dysplastic Epithelium and Oral Squamous Cell Carcinoma.

Authors:  Shokoufeh Shahrabi-Farahani; Marina Gallottini; Fabiana Martins; Erik Li; Dayna R Mudge; Hironao Nakayama; Kyoko Hida; Dipak Panigrahy; Patricia A D'Amore; Diane R Bielenberg
Journal:  Am J Pathol       Date:  2016-02-11       Impact factor: 4.307

Review 2.  Exosomes in diagnosis and therapy of prostate cancer.

Authors:  Jun Pan; Meng Ding; Kai Xu; Chunhua Yang; Li-Jun Mao
Journal:  Oncotarget       Date:  2017-06-17

3.  Keratin 13 expression reprograms bone and brain metastases of human prostate cancer cells.

Authors:  Qinlong Li; Lijuan Yin; Lawrence W Jones; Gina C-Y Chu; Jason B-Y Wu; Jen-Ming Huang; Quanlin Li; Sungyong You; Jayoung Kim; Yi-Tsung Lu; Stefan Mrdenovic; Ruoxiang Wang; Michael R Freeman; Isla Garraway; Michael S Lewis; Leland W K Chung; Haiyen E Zhau
Journal:  Oncotarget       Date:  2016-12-20

Review 4.  Exosomes are the Driving Force in Preparing the Soil for the Metastatic Seeds: Lessons from the Prostate Cancer.

Authors:  Saber H Saber; Hamdy E A Ali; Rofaida Gaballa; Mohamed Gaballah; Hamed I Ali; Mourad Zerfaoui; Zakaria Y Abd Elmageed
Journal:  Cells       Date:  2020-02-28       Impact factor: 6.600

5.  Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche.

Authors:  Catherine A Sánchez; Eliana I Andahur; Rodrigo Valenzuela; Enrique A Castellón; Juan A Fullá; Christian G Ramos; Juan C Triviño
Journal:  Oncotarget       Date:  2016-01-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.